KY 1005

Drug Profile

KY 1005

Alternative Names: KY1005

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kymab
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 29 May 2017 Phase-I clinical trials in Plaque psoriasis (In volunteers) in Netherlands (Parenteral)
  • 29 May 2017 Phase-I clinical trials in Plaque psoriasis in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top